Lantern Pharma Inc. Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial
TL;DR
Lantern Pharma's LP-300 combined with chemotherapy shows a durable complete response in a 70-year-old never-smoker with advanced NSCLC, offering a competitive edge in oncology treatments.
Lantern Pharma's Phase 2 HARMONIC trial demonstrates LP-300's efficacy in achieving a 57% tumor reduction and full resolution in a patient with advanced NSCLC, utilizing the RADR AI platform for development.
LP-300's success in treating a never-smoker with advanced NSCLC represents a significant step forward in addressing unmet needs for patients with limited treatment options, improving quality of life.
A 70-year-old never-smoker with advanced NSCLC achieved a durable complete response with Lantern Pharma's LP-300, showcasing the potential of AI in revolutionizing cancer treatment.
Found this article helpful?
Share it with your network and spread the knowledge!
Lantern Pharma Inc. (NASDAQ: LTRN) has achieved a notable milestone in its Phase 2 HARMONIC(TM) trial, with a 70-year-old never-smoker patient with advanced non-small cell lung cancer (NSCLC) experiencing a durable complete response after treatment with LP-300 combined with standard chemotherapy. This patient, who had previously undergone three unsuccessful lines of therapy, including Keytruda(R), radiation, and Tagrisso(R), initially witnessed a 57% reduction in tumor size, followed by the complete resolution of lung and adrenal lesions. Remarkably, nearly two years post-treatment initiation, the patient remains progression-free and has not reported any significant adverse effects over 21 treatment cycles.
This breakthrough highlights the potential of LP-300, developed using Lantern's RADR(R) AI platform, to meet a critical need in the treatment of never-smoker NSCLC patients who have exhausted other targeted therapy options. This group represents a growing segment of the population with few approved treatments available. The success of LP-300 in this trial could pave the way for new, effective treatment options for this underserved patient demographic, marking a significant advancement in the fight against NSCLC.
Curated from InvestorBrandNetwork (IBN)
